Switch to
More onapp

Marksans Pharma Ltd

MARKSANS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,897 cr, stock is ranked 673
Moderate RiskStock is 2.41x as volatile as Nifty
62.801.15 (-1.80%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,897 cr, stock is ranked 673
Moderate RiskStock is 2.41x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
15.70
PB RatioPB Ratio
2.37
Dividend YieldDiv. Yield
0.35%
Sector PESector PE
34.15
Sector PBSector PB
4.18
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Investor PresentationView older 

Nov 14, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

20192020202120221.001.131.381.530.080.120.240.18
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Updates 
Announced OnJan 24, 2023

Marksans Pharma Limited has informed the Exchange regarding 'Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018'. | Download

Marksans Pharma Limited has informed the Exchange regarding 'Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018'. | Download

Analysts/Institutional Investor Meet/Con. Call Updates 
Announced OnJan 24, 2023

Marksans Pharma Limited has informed the Exchange about Schedule of meet | Download

Marksans Pharma Limited has informed the Exchange about Schedule of meet | Download

Cash Dividend 
Ex. DateAug 19, 2022

Final • Div/Share: ₹ 0.25

See all events